Literature DB >> 12359324

Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.

Konrad Rejdak1, Halina Bartosik-Psujek, Beata Dobosz, Tomasz Kocki, Pawelz Grieb, Gavin Giovannoni, Waldemar A Turski, Zbigniew Stelmasiak.   

Abstract

The present study was undertaken to measure cerebrospinal fluid (CSF) levels of kynurenic acid (KYNA) in patients with relapsing-onset multiple sclerosis (MS) during remission or not progressing for at least 2 months. In these patients the levels of CSF KYNA were found to be significantly lower compared with subjects with non-inflammatory neurological diseases, as well as those with inflammatory disease (median (interquartile range): 0.41 (0.3-0.5) pmol/ml, n=26 vs. 0.67 (0.5-1.1), n=23, P<0.01 and 1.7 (1.5-2.6), n=16, P<0.001, respectively). These results provide further evidence of the alterations in the kynurenine pathway during remitting-onset MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359324     DOI: 10.1016/s0304-3940(02)00710-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

1.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

Review 2.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

Review 3.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

4.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 5.  The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.

Authors:  Judit Füvesi; Cecilia Rajda; Krisztina Bencsik; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-01-19       Impact factor: 3.575

6.  Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.

Authors:  Jonathan Savitz; Robert Dantzer; Brent E Wurfel; Teresa A Victor; Bart N Ford; Jerzy Bodurka; P S F Bellgowan; T Kent Teague; Wayne C Drevets
Journal:  Psychoneuroendocrinology       Date:  2014-11-24       Impact factor: 4.905

Review 7.  IDO expression in the brain: a double-edged sword.

Authors:  Erik Kwidzinski; Ingo Bechmann
Journal:  J Mol Med (Berl)       Date:  2007-06-27       Impact factor: 4.599

Review 8.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

9.  Understanding the roles of the kynurenine pathway in multiple sclerosis progression.

Authors:  Chai K Lim; Bruce J Brew; Gayathri Sundaram; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2010-08-25

10.  The physiological action of picolinic Acid in the human brain.

Authors:  R S Grant; S E Coggan; G A Smythe
Journal:  Int J Tryptophan Res       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.